United Therapeutics Corporation (UTHR)

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Tyvaso Revenue	1.87B	1.88B	1.62B
Tyvaso Revenue Growth	-0.47%	15.91%	31.34%
Remodulin Revenue	515.20M	526.80M	538.10M
Remodulin Revenue Growth	-2.20%	-2.10%	8.75%
Orenitram Revenue	511.80M	496.90M	434.30M
Orenitram Revenue Growth	3.00%	14.41%	20.84%
Unituxin Revenue	222.20M	226.80M	238.70M
Unituxin Revenue Growth	-2.03%	-4.98%	20.01%
Adcirca Revenue	26.90M	30.00M	23.80M
Adcirca Revenue Growth	-10.33%	26.05%	-17.65%
Total Product Sales Revenue	3.15B	3.16B	2.86B
Total Product Sales Revenue Growth	-0.25%	10.63%	23.30%
Revenue (Other)	19.00M	24.00M	22.10M
Revenue (Total)	3.17B	3.18B	2.88B
Revenue (Total) Growth	-0.40%	10.61%	23.63%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
United States Revenue	3.03B	3.04B	2.74B
United States Revenue Growth	-0.18%	10.85%	24.41%
Rest-of-World Revenue	138.20M	145.70M	137.70M
Rest-of-World Revenue Growth	-5.15%	5.81%	9.90%
Revenue (Total)	3.17B	3.18B	2.88B
Revenue (Total) Growth	-0.40%	10.61%	23.63%

Gross Profit

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Tyvaso Gross Profit	1.60B	1.64B	1.44B
Tyvaso Gross Profit Growth	-2.68%	14.08%	32.44%
Remodulin Gross Profit	463.60M	477.50M	490.70M
Remodulin Gross Profit Growth	-2.91%	-2.69%	7.47%
Orenitram Gross Profit	484.00M	468.20M	405.90M
Orenitram Gross Profit Growth	3.38%	15.35%	21.09%
Unituxin Gross Profit	204.90M	209.30M	224.30M
Unituxin Gross Profit Growth	-2.10%	-6.69%	22.97%
Adcirca Gross Profit	15.40M	16.90M	13.70M
Adcirca Gross Profit Growth	-8.88%	23.36%	-17.47%
Total Product Sales Gross Profit	2.76B	2.81B	2.57B
Total Product Sales Gross Profit Growth	-1.95%	9.32%	23.89%
Gross Profit (Other)	-13.00M	-14.00M	-4.80M
Gross Profit (Total)	2.74B	2.80B	2.57B
Gross Profit (Total) Growth	-1.92%	8.98%	24.04%

Updated May 6, 2026. Data Source: Fiscal.ai.